Arena Pharmaceuticals Inc (ARNA.OQ)
Tue, May 8 2018
* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018
BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8
* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:
* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering
* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.
March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.
- Your Daily Pharma Scoop: Arena Positive, Omeros's New Designation, Zai Lab's Phase 3 Dosing Begins
- Is The Bottom In For Celgene?
- Liquidia: Is It Worth Getting On Board Early?
- United Therapeutics Releases Positive Data On PAH Drug - What Investors Should Know.
- Arena Reports Loss As Expected - Pipeline Will Drive The Stock
- Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q2 2018 Results - Earnings Call Transcript